Cassava will stop developing simufilam for Alzheimer’s this year after a Phase 3 trial failed to improve cognition and daily ...
Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback